|
Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis] |
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C. Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil. [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 302. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related aspects regarding the use of etanercept, adalimumab, infliximab and golimumab in patients with Juvenile Idiopathic Arthritis. Authors' conclusions The evidence found is high quality. JIA treatment with etanercept and adalimumab has demonstrated to improve disease relapse. The use of etanercept is accepted by regulatory agencies, health sponsors and CPG. The use of adalimumab is less homogeneous and depends on local costs and availability. Infliximab has not been approved by the FDA and ANMAT and golimumab is under Phase II research for JIA. They are indicated for patients 4 to 17 years old whose disease remains active with involvement in 5 or more joints after 3-6 months of treatment with methotrexate and another disease-modifying drug. They are not recommended for systemic forms with no joint involvement. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Arthritis, Juvenile; Arthritis, Rheumatoids; Immunoglobulin G; Receptors, Tumor Necrosis Factor Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32014000261 Date abstract record published 28/01/2014 |
|
|
|